1. Home
  2. GKOS vs ESE Comparison

GKOS vs ESE Comparison

Compare GKOS & ESE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$107.89

Market Cap

5.4B

Sector

Health Care

ML Signal

HOLD

Logo ESCO Technologies Inc.

ESE

ESCO Technologies Inc.

HOLD

Current Price

$200.36

Market Cap

5.5B

ML Signal

HOLD

Company Overview

Basic Information
Metric
GKOS
ESE
Founded
1998
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Telecommunications Equipment
Sector
Health Care
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
5.5B
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
GKOS
ESE
Price
$107.89
$200.36
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
2
Target Price
$122.08
$237.50
AVG Volume (30 Days)
1.1M
216.3K
Earning Date
10-29-2025
11-20-2025
Dividend Yield
N/A
0.16%
EPS Growth
N/A
193.11
EPS
N/A
11.55
Revenue
$469,820,000.00
$1,095,388,000.00
Revenue This Year
$30.89
$18.95
Revenue Next Year
$24.36
$6.83
P/E Ratio
N/A
$17.37
Revenue Growth
30.38
6.68
52 Week Low
$73.16
$127.17
52 Week High
$163.71
$229.46

Technical Indicators

Market Signals
Indicator
GKOS
ESE
Relative Strength Index (RSI) 73.56 36.42
Support Level $104.11 $211.27
Resistance Level $107.18 $227.46
Average True Range (ATR) 4.40 9.35
MACD 1.26 -2.02
Stochastic Oscillator 92.97 2.00

Price Performance

Historical Comparison
GKOS
ESE

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About ESE ESCO Technologies Inc.

ESCO Technologies Inc sells engineered products and systems for utility, industrial, aerospace, and commercial applications. The firm operates in three segments: Aerospace and Defense, Utility Solutions Group (USG), and Test. The Aerospace and Defense segment designs and manufactures specialty filtration and naval products. The USG segment provides diagnostic testing solutions. The Test segment provides its customers with the ability to identify, measure, and contain magnetic, electromagnetic, and acoustic energy.

Share on Social Networks: